Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 9Active not recruiting 9Withdrawn 4Terminated 4Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Chordoma 1

Interventions

pembrolizumab 6avelumab 4Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ALT-803 2yeast-CEA vaccine 1vadimezan 1trebananib 1obinutuzumab 1naptumomab estafenatox 1erdafitinib 1enfortumab vedotin 1bicalutamide 1atezolizumab 1Ultrasonography 1Specimen Handling 1Ramucirumab 1Radiosurgery 1Phantoms, Imaging 1PM 01183 1Omacor 1Nivolumab 1Neoadjuvant Therapy 1Mitomycin 1Lycopene 1Leucovorin 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Transitional Cell × avelumab × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

EMD Serono

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

AdventHealth

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05107427 2023-04-18

AVENU

4D pharma plc

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡